Skip to main content
20 November 2026

Vertex and Genomics Expand Human Genetics Collaboration for Novel Therapies

Genomics, a science-led Techbio company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development, announced a four-year extension of its long-standing drug target discovery and validation collaboration with Vertex Pharmaceuticals. The extension builds on an eight-year collaboration which originally commenced in 2018.

Scientists from Vertex and Genomics will continue to work closely together to incorporate their deep understanding of human genetics into research and development. The collaboration focuses on using human genetics for the discovery and validation of novel drug targets and biomarker selection for precision medicines, and to advance understanding of the clinical impact of human genetic variation in diseases with significant unmet need.

"A deep understanding of human genetics and the underlying causal biology of diseases is foundational to how we discover and develop transformational therapies at Vertex," said Mark Bunnage, Executive Vice President and Chief Scientific Officer at Vertex Pharmaceuticals. "Over nearly a decade together, Genomics has proven to be an exceptional partner, combining sophisticated data science with deep genetic insights, and I'm delighted to be extending our productive partnership." 

"We are proud to extend our collaboration with Vertex. Over the last eight years, it has demonstrated the power of human genetics to identify and validate the right drug targets to develop next-generation medicines and help people live longer, healthier lives. Our unique platform and our proprietary algorithms allow us to bring the full power of human genetics to understand key biological processes driving disease and to use those insights to find novel targets and powerful biomarkers. Extending this partnership allows us to scale that approach and accelerate the delivery of novel, precision medicines for patients who need them most," said Professor Sir Peter Donnelly, co-Founder and Chief Executive Officer at Genomics. "We are delighted to continue working with one of the most innovative and successful companies in the global biotech sector to help realise that promise to benefit patients and their families."

Science Minister Chris McDonald said: "Genome science is transforming how we treat and beat disease. Using information which is embedded in our DNA, Genomics and Vertex are able to use that data to identify promising new drugs and treatments; improving healthcare outcomes across the UK.

slot gacor